Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00697684 · ClinicalTrials.gov registry record · Phase 1
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
A Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00697684 is a Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 29 participants.
The verdict
NCT00697684, a Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study will examine the safety of clofarabine, TLI and ATG as a reduced conditioning regimen prior to allogeneic transplantation. The impact of the conditioning regimen on the presence of the circulating regulatory as compared to activated T cell populations will be assessed.The recovery of DC populations post-transplant will be examined, along with the effect of the regimen on disease free and overall survival.
Interventions
- DRUG Clofarabine
- DRUG Antithymocyte Globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2008-06 |
| Est. Completion | 2023-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00697684
The ClinicalTrials.gov registry entry for NCT00697684 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clofarabine is the first listed.
NCT00697684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00697684 about?
NCT00697684 is a clinical study titled "Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant". This study will examine the safety of clofarabine, TLI and ATG as a reduced conditioning regimen prior to allogeneic transplantation. The impact of the conditioning regimen on the presence of the circulating regulatory as compared to activated T cell populations will be assessed.The recovery of DC p...
What is the current status of trial NCT00697684?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2008-06. Estimated completion is 2023-11.
What interventions are being tested in trial NCT00697684?
The interventions under investigation include: Clofarabine (DRUG), Antithymocyte Globulin (DRUG).
Who is sponsoring clinical trial NCT00697684?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.